HUMULIN R (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1982.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
HUMULIN R is a rapid-acting human insulin injection approved by the FDA in 1982 for the treatment of diabetes mellitus. It works by regulating glucose metabolism through stimulation of peripheral glucose uptake in skeletal muscle and fat tissue, while simultaneously inhibiting hepatic glucose production. The drug also suppresses lipolysis and proteolysis while enhancing protein synthesis. As a short-acting insulin, HUMULIN R is a foundational diabetes therapy typically used for prandial (mealtime) glycemic control, often in combination with longer-acting basal insulins.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Worked on HUMULIN R at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHUMULIN R creates pharmaceutical career opportunities primarily in brand management, medical science liaisons (MSLs), and field sales roles focused on hospital formulary management and payer relationships. Success in this role requires deep knowledge of insulin pharmacology, diabetes management protocols, injection technique training, and payer negotiation skills, given intense price competition. Currently, zero open job positions are linked to this specific product, reflecting the mature market stage and reduced commercial investment as the product approaches generic competition.